Phase 2 N=85 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 4.8 months
Phase 2 N=111 Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 7.1 months
Phase 2 N=48 Effects of CLA Supplements on Body Weight and Fat Oxidation
Obesity
Primary: Fat Mass — -1.0; 0.7 kg — p=<0.05
Phase 2 N=153 Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
HIV Infections
Primary: Percentage of Participants With Grade 3 or 4 Adverse Events (AEs) — 20.3; 25; 15.4; 30 percentage of participants
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=119 High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Renal Cancer · Kidney Cancer
Primary: Progression-free Survival — 6.0; 5.7 months
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter
Phase 2 N=52 A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
Non-Small Cell Lung Cancer
Primary: Non-Progression Rate (NPR) at 8 Weeks — 41.4; 65.2 percentage of participants
Phase 2 N=132 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Lip and Oral Cavity Cancer · Oral Leukoplakia · Oropharyngeal Cancer
Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change
Phase 2 N=273 A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28 — 40.0; 52.7; 54.5; 44.4 percentage of participants — p=0.184
Phase 2 N=41 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Melanoma (Skin)
Primary: Evaluation of Objective Clinical Response (CR/PR/SD) — 0; 0; 1; 2 participants
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
Phase 2 N=40 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Recurrent Chronic Hepatitis C Virus · Post Liver Transplant
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 70.0 percentage of participants
Phase 2 N=68 Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Lymphoma
Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants